Comparing the current results to its competitors, Lexeo Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 13.03 %, recorded in the same quarter.
April 22, 2024
Lexeo Therapeutics, a leading name in genetic medicine, has recently announced an arrangement empowering them to fast-track the development of their novel treatment for a rare disorder, Friedreich Ataxia Cardiomyopathy (FAC). The company has secured the rights to intellectual property, inclusive of pivotal trial data, from Weill Cornell Medicine, in relation to gene therapy candidate AAVrh.10hFXN, also known as LX2006, which will expedite the regulatory discussion processes. FAC is a health condition primarily affecting the heart, and is one of the most common symptoms of Friedreich’s ataxia (FA), a rare neurodegenerative disease. The extensively prevalent and severe cardiomyopathy implores the need for ef...
Lexeo Therapeutics, a pioneering biotech company, has been granted Fast Track Designation and Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for their revolutionary gene therapy candidate, LX2020. Developed as a potential treatment for PKP2 Arrhythmogenic Cardiomyopathy (ACM), this AAV-based gene therapy holds immense promise for patients suffering from this life-threatening condition. This significant regulatory recognition not only underscores the urgent need for innovative therapies in this space but also paves the way for accelerated development and potential marketing approval. Fast Track Designation: Expediting Critical Therapeutics The FDA s Fast Track Designa...
Compass Therapeutics Inc operates as a biotechnology company focused on discovering and developing novel antibody therapeutics for the treatment of cancer and autoimmune diseases. Their business model revolves around leveraging their proprietary Targeted Immunomodulation platform to identify and advance multiple antibody candidates through preclinical and clinical development stages.
Cardiol Therapeutics Inc. operates on a business model focused on the research and development of pharmaceutical-grade cannabidiol (CBD) and targeted therapies for cardiovascular diseases. The company aims to leverage its expertise to develop innovative and effective treatments to address unmet medical needs in the field of heart-related conditions.
Estrella Immunopharma Inc is a biotechnology company that focuses on developing innovative immunotherapies. They have a business model centered around researching, developing, and commercializing novel treatments for various diseases. Their approach includes leveraging the power of the immune system to target and eradicate diseases, with a particular emphasis on cancer.
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
Sources:
Lexeo Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Lexeo Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
